Azacitidine-venetoclax showed superior event-free survival and overall response rates compared to traditional induction chemotherapy in AML patients. The study highlighted reduced hospital stays, ...

Collaboration to focus on building a leading, US-based biotech dedicated to addressing underserved patients impacted by autoimmune and endocrinology disorders GenSci to receive $70 million ...

Acute myeloid leukemia is a type of cancer that starts inside bone marrow, the soft tissue inside bones that helps form blood cells. The cancer develops from myeloid blasts cells that would normally ...

AML develops quickly, with symptoms like bone pain and shortness of breath, while CML progresses slowly and can start with weight loss and night sweats. AML is more common in both children and adults, ...

Azacitidine/venetoclax reduced the risk of disease progression, relapse, or death by 39% compared with induction chemotherapy in AML patients, improving event-free ...

Acute Myeloid Leukemia (AML) is a rare and aggressive blood cancer. The earliest sign of AML is often feeling very tired. Certain risk factors like smoking and being over 65 can increase the chances ...

Turkmenistan has legalized cryptocurrency mining and trading after a new law came into effect on Jan. 1. The landlocked Central Asian nation, which holds roughly 10% of the global natural gas reserves ...

Pirtobrutinib showed noninferiority in ORR compared to ibrutinib in BTK inhibitor-naive CLL/SLL patients, with a favorable PFS trend. Safety profiles indicated fewer adverse events with pirtobrutinib, ...